RXST
RxSight, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-47/100
Last price
4.65
▼ 0.11 (2.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.76
Prev close
4.76
Day high
4.76
Day low
4.60
Volume
623.01K
Market cap
$193.41M
P/E (TTM)
—
52W range
4.48 – 13.22
Day trading desk
Gap from prior close
-0.00%
Prior close 4.76
VWAP
4.65
-0.06% from price
Relative volume
1.34×
Normal
Session range
4.35%
4.60 – 4.80
Position in range
25%
Near session low
ATR (14D)
0.21
4.59% of price
Prior day high
4.80
PDH
Prior day low
4.62
PDL
Bid / ask spread
—
Quote not published
Session volume
1.17M
Avg 873.60K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.52%
-4.5%
1M
-27.06%
-28.2%
3M
-12.92%
-17.4%
6M
-31.21%
-49.4%
YTD
-55.37%
-69.6%
1Y
-47.16%
-63.6%
3Y
-83.33%
-165.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on RXST open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+402.48K
Net buying
Buy transactions
15
419.42K shares
Sell transactions
4
16.95K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
2.73M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | WEINBERG ERIC Officer |
CONVERSION | 35.17K | $152.63K | Direct |
| Sep 2, 26 | WEINBERG ERIC Officer |
SELL | 2.04K | $14.21K | Direct |
| Sep 2, 26 | KURTZ RONALD M Officer |
SELL | 5.10K | $35.50K | Direct |
| Sep 2, 26 | GOLDSHLEGER ILYA Chief Operating Officer |
SELL | 2.04K | $14.21K | Direct |
| Sep 2, 26 | WILTERDING MARK Chief Financial Officer |
SELL | 7.76K | $54.04K | Direct |
| Aug 31, 26 | WEINBERG ERIC Officer |
— | 5.37K | — | Direct |
| Aug 31, 26 | KURTZ RONALD M Officer |
— | 13.43K | — | Direct |
| Aug 31, 26 | GOLDSHLEGER ILYA Chief Operating Officer |
— | 5.37K | — | Direct |
| Aug 31, 26 | WILTERDING MARK Chief Financial Officer |
— | 20.44K | — | Direct |
| Jun 17, 26 | PALMISANO ROBERT J Director |
STOCK | 37.04K | $0 | Direct |
| Jun 17, 26 | COHEN RAYMOND W Director |
STOCK | 30.86K | $0 | Direct |
| Jun 17, 26 | ANDREWS JULIE Director |
STOCK | 37.04K | $0 | Direct |
| Jun 17, 26 | TAMMENOMS BAKKER JULIET Director |
STOCK | 37.04K | $0 | Direct |
| Jun 17, 26 | LINK WILLIAM J Director |
STOCK | 37.04K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDREWS JULIE |
Director | 78.08K | Stock Award(Grant) |
CORLEY JESSE ANDERSON |
Director | 589.37K | Stock Award(Grant) |
FOUNTAIN TAMARA R. |
Director | 72.58K | Stock Award(Grant) |
GOLDSHLEGER ILYA |
Chief Operating Officer | 82.88K | Sale |
KURTZ RONALD M |
Officer | 836.38K | Sale |
LINK WILLIAM J |
Director | 96.14K | Stock Award(Grant) |
PALMISANO ROBERT J |
Director | 78.08K | Stock Award(Grant) |
TAMMENOMS BAKKER JULIET |
Director | 86.73K | Stock Award(Grant) |
WARNER ROBERT KEITH |
Director | 78.08K | Stock Award(Grant) |
WEINBERG ERIC |
Officer | 536.42K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$193.41M
Enterprise value$-4.81M
Revenue (TTM)$127.58M
Gross profit$98.88M
EBITDA$-51.58M
Net income$-46.95M
EPS (TTM)$-1.14
Free cash flow$-6.73M
Total cash$208.80M
Total debt$10.58M
Book value / share$6.33
Shares outstanding41.59M
Float33.71M
Short % of float10.09%
Dividend yield0.00%
Beta (5Y)1.14
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.67
PEG ratio—
Price / sales—
Price / book0.73
EV / revenue-0.04
EV / EBITDA0.09
Gross margin77.50%
Operating margin-40.81%
Profit margin-36.80%
Return on equity-17.34%
Return on assets-10.41%
Debt / equity4.02
Current ratio4.07
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $134.48M | $139.93M | $89.08M | $49.01M | -3.9% |
| Operating revenue | $134.48M | $139.93M | $89.08M | $49.01M | -3.9% |
| Cost of revenue | $31.47M | $40.98M | $35.31M | $27.68M | -23.2% |
| Gross profit | $103.01M | $98.94M | $53.77M | $21.33M | +4.1% |
| Research & development | $38.55M | $34.37M | $29.05M | $25.98M | +12.2% |
| Selling, general & admin | $112.65M | $101.43M | $74.80M | $58.66M | +11.1% |
| Total operating expense | $151.20M | $135.80M | $103.85M | $84.65M | +11.3% |
| Operating income | -$48.19M | -$36.86M | -$50.09M | -$63.32M | -30.7% |
| Net interest income | $9.31M | $9.45M | $3.27M | -$3.43M | -1.5% |
| Pre-tax income | -$38.88M | -$27.41M | -$48.59M | -$66.75M | -41.9% |
| Tax provision | $66.00K | $50.00K | $20.00K | $9.00K | +32.0% |
| Net income | -$38.94M | -$27.45M | -$48.61M | -$66.76M | -41.8% |
| Net income to common | -$38.94M | -$27.45M | -$48.61M | -$66.76M | -41.8% |
| Basic EPS | -0.95 | -0.71 | -1.41 | -2.41 | -33.8% |
| Diluted EPS | -0.95 | -0.71 | -1.41 | -2.41 | -33.8% |
| EBIT | -$38.86M | -$27.38M | -$45.28M | -$61.80M | -41.9% |
| EBITDA | -$35.59M | -$23.81M | -$41.20M | -$57.78M | -49.5% |
| Basic shares | 40.85M | 38.87M | 34.46M | 27.66M | +5.1% |
| Diluted shares | 40.85M | 38.87M | 34.46M | 27.66M | +5.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.95M | $16.71M | $9.69M | $11.83M | — | +19.4% |
| Cash & short-term investments | $228.13M | $237.22M | $127.18M | $105.80M | — | -3.8% |
| Accounts receivable | $23.38M | $30.05M | $20.28M | $10.96M | — | -22.2% |
| Inventory | $31.56M | $22.01M | $17.42M | $14.84M | — | +43.4% |
| Total current assets | $287.46M | $293.82M | $168.41M | $134.56M | — | -2.2% |
| Property, plant & equipment | $23.02M | $23.63M | $13.29M | $14.08M | — | -2.6% |
| Total assets | $311.81M | $318.56M | $182.55M | $150.16M | — | -2.1% |
| Total current liabilities | $26.25M | $25.88M | $20.90M | $17.24M | — | +1.5% |
| Long-term debt | — | — | — | $40.17M | $39.76M | — |
| Total debt | $11.04M | $12.30M | $3.01M | $44.99M | — | -10.2% |
| Total liabilities | $36.13M | $37.33M | $22.19M | $60.26M | — | -3.2% |
| Retained earnings | -$661.04M | -$622.10M | -$594.64M | -$546.03M | — | -6.3% |
| Shareholder equity | $275.68M | $281.24M | $160.36M | $89.90M | — | -2.0% |
| Working capital | $261.21M | $267.95M | $147.50M | $117.32M | — | -2.5% |
| Net tangible assets | $275.68M | $281.24M | $160.36M | $89.90M | — | -2.0% |
| Shares issued | 41.24M | 40.43M | 36.14M | 28.27M | — | +2.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$38.94M | -$27.45M | -$48.61M | -$66.76M | -41.8% |
| Depreciation & amortisation | $3.27M | $3.58M | $4.08M | $4.02M | -8.6% |
| Stock-based compensation | $31.61M | $24.64M | $15.75M | $11.40M | +28.3% |
| Change in working capital | -$4.89M | -$9.16M | -$8.91M | -$7.41M | +46.6% |
| Operating cash flow | -$15.51M | -$16.95M | -$41.59M | -$58.85M | +8.5% |
| Capital expenditure | -$3.83M | -$5.44M | -$4.81M | -$2.39M | +29.6% |
| Investing cash flow | $16.89M | -$99.31M | -$22.13M | $39.95M | +117.0% |
| Financing cash flow | $1.86M | $123.32M | $61.52M | $6.33M | -98.5% |
| Free cash flow | -$19.34M | -$22.39M | -$46.41M | -$61.24M | +13.6% |
| End cash position | $20.70M | $17.46M | $10.40M | $12.60M | +18.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $33.74M | $30.89M | $32.61M | $30.34M | $33.64M | +9.2% |
| Operating revenue | $33.74M | $30.89M | $32.61M | $30.34M | $33.64M | +9.2% |
| Cost of revenue | $7.86M | $7.39M | $7.34M | $6.11M | $8.45M | +6.2% |
| Gross profit | $25.89M | $23.50M | $25.26M | $24.23M | $25.19M | +10.2% |
| Research & development | $9.24M | $9.47M | $8.90M | $9.06M | $10.22M | -2.5% |
| Selling, general & admin | $30.42M | $31.86M | $27.70M | $27.34M | $28.98M | -4.5% |
| Total operating expense | $39.66M | $41.33M | $36.60M | $36.41M | $39.19M | -4.0% |
| Operating income | -$13.77M | -$17.83M | -$11.34M | -$12.18M | -$14.00M | +22.8% |
| Net interest income | $1.76M | $1.95M | $2.19M | $2.37M | $2.25M | -9.7% |
| Pre-tax income | -$12.01M | -$15.88M | -$9.15M | -$9.81M | -$11.75M | +24.4% |
| Tax provision | $88.00K | $6.00K | $5.00K | $10.00K | $32.00K | +1,366.7% |
| Net income | -$12.10M | -$15.88M | -$9.15M | -$9.82M | -$11.79M | +23.8% |
| Net income to common | -$12.10M | -$15.88M | -$9.15M | -$9.82M | -$11.79M | +23.8% |
| Basic EPS | -0.29 | -0.38 | -0.22 | -0.24 | -0.29 | +23.7% |
| Diluted EPS | -0.29 | -0.38 | -0.22 | -0.24 | -0.29 | +23.7% |
| EBIT | -$12.01M | -$15.88M | -$9.14M | -$9.80M | -$11.75M | +24.4% |
| EBITDA | -$11.01M | -$15.04M | -$8.29M | -$8.95M | -$10.97M | +26.8% |
| Basic shares | 41.49M | 41.31M | 41.18M | 40.97M | 40.74M | +0.4% |
| Diluted shares | 41.49M | 41.31M | 41.18M | 40.97M | 40.74M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.35M | $17.57M | $19.95M | $29.63M | $40.35M | -24.0% |
| Cash & short-term investments | $208.80M | $217.88M | $228.13M | $227.52M | $227.49M | -4.2% |
| Accounts receivable | $18.52M | $22.44M | $23.38M | $24.15M | $28.06M | -17.5% |
| Inventory | $37.12M | $34.87M | $31.56M | $28.95M | $25.06M | +6.4% |
| Total current assets | $327.40M | $279.23M | $287.46M | $283.88M | $283.87M | +17.3% |
| Property, plant & equipment | $23.53M | $22.99M | $23.02M | $23.37M | $23.84M | +2.3% |
| Total assets | $352.70M | $303.99M | $311.81M | $308.53M | $309.01M | +16.0% |
| Total current liabilities | $80.44M | $27.38M | $26.25M | $22.29M | $20.38M | +193.8% |
| Total debt | $10.58M | $10.83M | $11.04M | $11.56M | $11.71M | -2.3% |
| Total liabilities | $89.36M | $36.70M | $36.13M | $32.56M | $31.00M | +143.5% |
| Retained earnings | -$689.02M | -$676.92M | -$661.04M | -$651.89M | -$642.07M | -1.8% |
| Shareholder equity | $263.34M | $267.30M | $275.68M | $275.97M | $278.01M | -1.5% |
| Working capital | $246.95M | $251.85M | $261.21M | $261.59M | $263.49M | -1.9% |
| Net tangible assets | $263.34M | $267.30M | $275.68M | $275.97M | $278.01M | -1.5% |
| Shares issued | 41.59M | 41.38M | 41.24M | 41.08M | 40.91M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$12.10M | -$15.88M | -$9.15M | -$9.82M | -$11.79M | +23.8% |
| Depreciation & amortisation | $999.00K | $834.00K | $851.00K | $854.00K | $776.00K | +19.8% |
| Stock-based compensation | $7.46M | $7.95M | $7.82M | $8.11M | $8.55M | -6.0% |
| Change in working capital | -$5.47M | -$1.99M | $584.00K | $1.75M | -$1.01M | -174.8% |
| Operating cash flow | -$9.54M | -$10.89M | -$1.12M | -$1.19M | -$4.38M | +12.4% |
| Capital expenditure | -$1.96M | -$759.00K | -$1.14M | -$581.00K | -$1.54M | -157.7% |
| Investing cash flow | $4.65M | $8.85M | -$9.61M | -$9.00M | $14.65M | -47.4% |
| Financing cash flow | $662.00K | -$336.00K | $1.06M | -$530.00K | $2.06M | +297.0% |
| Free cash flow | -$11.49M | -$11.65M | -$2.25M | -$1.77M | -$5.91M | +1.3% |
| End cash position | $14.10M | $18.32M | $20.70M | $30.38M | $41.10M | -23.0% |
Options analytics
Put / call volume
0.07
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
-46.2% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
+37.5%
Puts bid over calls
Call volume
15
Contracts, this expiry
Put volume
1
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
2.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | -0.11 | +41.4% |
| Mar 2026 | -0.15 | -0.19 | -28.4% |
| Dec 2025 | -0.20 | -0.03 | +84.8% |
| Sep 2025 | -0.26 | -0.04 | +84.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.15 | 5 | $27.19M | -10.4% |
| Next quarter | 0.18 | 5 | $55.20M | +69.3% |
| Current year | -0.27 | 5 | $147.06M | +9.4% |
| Next year | -0.70 | 5 | $149.16M | +1.4% |
Analyst targets & ownership
Mean target$7.57
High target$11.00
Low target$5.50
Implied upside62.77%
Analyst count8
ConsensusHOLD
Strong buy / Buy1 / 0
Hold7
Sell / Strong sell0 / 2
Held by insiders6.57%
Held by institutions104.52%
Institutions holding205
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.74
-1.94% from price
SMA 20
5.17
-10.10% from price
SMA 50
5.96
-22.04% from price
SMA 100
5.63
-17.33% from price
SMA 200
6.89
-32.47% from price
EMA 12
4.90
-5.13% from price
EMA 26
5.30
-12.24% from price
EMA 50
5.59
-16.83% from price
RSI (14)
31.3
Neutral
MACD (12,26,9)
-0.40
Hist -0.02
ATR (14)
0.21
4.59% of price
Realised vol 30D
52.2%
Annualised
Bollinger upper
6.25
20, 2σ
Bollinger lower
4.10
20, 2σ
50 / 200 cross
Death
5.96 vs 6.89
Trend bias
Below 200
-32.47%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.14
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
52.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-64.9%
Peak to trough
Max drawdown 5Y
-92.9%
Peak to trough
ATR 14
0.21
4.59% of price
Beta (reported)
1.14
5Y monthly, from filing
Short interest
Shares short
3.98M
Prior 4.26M
Change vs prior
-6.7%
Shorts covering
% of float
10.09%
Elevated
% of shares out
9.56%
Against total outstanding
Days to cover
5.0
Crowded exit
Float
33.71M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | Jefferies | MAINTAINED | Hold | Hold |
| Sep 22, 26 | B of A Securities | MAINTAINED | Underperform | Underperform |
| Aug 10, 26 | Stifel | MAINTAINED | Hold | Hold |
| Aug 6, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Jul 7, 26 | B of A Securities | MAINTAINED | Underperform | Underperform |
| Jul 7, 26 | Needham | MAINTAINED | Buy | Buy |
| May 7, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| May 7, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 9, 26 | Stifel | MAINTAINED | Hold | Hold |
| Feb 26, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Feb 26, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Feb 26, 26 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Tender Offer/Acquisition Reports
SC TO-I/A · 2026-09-08
Tender Offer/Acquisition Reports
SC TO-I/A · 2026-08-25
Tender Offer/Acquisition Reports
SC TO-I · 2026-08-10
Periodic Financial Reports
10-Q · 2026-08-05
Offering Registrations
S-8 · 2026-07-23
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-16
Headlines
RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
MT Newswires · 14d ago
BofA Adjusts Price Target on RxSight to $5.50 From $6.50
MT Newswires · 15d ago
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
GlobeNewswire · 41d ago
Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?
Insider Monkey · 54d ago
RxSight (RXST) Q2 2026 Earnings Call Transcript
Motley Fool · 55d ago
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside
GuruFocus.com · 62d ago
RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ...
GuruFocus.com · 62d ago
RxSight Q2 Earnings Call Highlights
MarketBeat · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.